From VFC's News, Notes & Weekly Stock Watch at VFC's NEW Stock House:
CVM: The company filed a schedule 14A last week outlining an upcoming shareholder meeting that will sort out compensation packages for senior management and directors.
Yes, this is the same team that partied it up in Prague a couple of months ago, announced the commencement of the global Phase III trial for Multikine, but has yet to announce that one patient has enrolled in the trial.
This company holds boatloads of potential should Multikine be proven a success during the upcoming trial, but for a company that has announced just about every single site approval, I'm starting to wonder why there has not been a patient enrolled just yet.
It's been a tough couple of years for the company, in terms of staying afloat while the Multikine production facility was constructed near Baltimore, Maryland, but it's not going to sit well with shareholders to see significant compensation packages voted on before a patient is enrolled in this trial.
I'll chalk up the Czech Pilsner as a cost of operations, but let's see some developments now before discussing the compensation.
Everything but the kitchen sink - and first enrollment - has been announced via PR over the past few months, but it looks the company tried to slip this 14A past the shareholders on a Friday.
Keep an eye on Cel-Sci, loads of potential, but where's that first patient?
Disclosure: Long CVM.